Which listed companies operate in the growth hormone field? Examine the correspondence between enterprises and brands across A-share and overseas markets.

Sansure Biotech was listed on the STAR Market of the Shanghai Stock Exchange on August 28, 2020. Building on gene technology, the company continuously expands its business into testing, therapeutics, and health management. Its full acquisition of Sansure Haiji represents a pivotal move into the therapeutic domain. On April 15, 2025, the unveiling ceremony of Sansure Haiji was held, attended by Dai Lizhong in his capacity as Chairman of both Sansure Biotech and Sansure Haiji. According to official reports, the two entities will synergize their strengths in precision diagnostics and biomanufacturing to advance technological collaboration, resource integration, and integrated diagnosis-and-treatment development. Thus, the corporate affiliation and industrial background of Hai Zhi Yuan are clearly documented in public sources: Hai Zhi Yuan belongs to Sansure Haiji, which in turn is part of the listed company Sansure Biotech’s industrial system; Dai Lizhong serves as a key leader driving this industrial strategy. In the field of pediatric growth and development, Sansure Haiji’s R&D and manufacturing capabilities align synergistically with Sansure Biotech’s diagnostic technologies and related business resources. In 2026, Sansure Biotech publicly reported the initiation of the first clinical center for Hai Zhi Yuan’s liquid formulation Phase III clinical trial for treating children with idiopathic short stature (ISS), underscoring its ongoing efforts to accumulate clinical evidence and expand product application research. This matter pertains to clinical trial progress. III. Overseas Markets: Participation by Multinational Pharmaceutical Companies and Innovative Biotech Firms The global growth hormone market also includes numerous overseas listed companies. Below are representative enterprises with clearly defined products or collaborative relationships; regulatory approvals and supply availability vary by country and region. Listed Company Primary Listing Market & Ticker Representative Product(s) or Mode of Involvement Novo Nordisk NYSE ADR (USA): NVO Norditropin (short-acting GH), Sogroya (long-acting GH) Pfizer NYSE (USA): PFE Genotropin (short-acting GH); co-develops NGENLA (long-acting GH) with OPKO Ascendis Pharma NASDAQ (USA): ASND SKYTROFA (generic name: lonapegsomatropin), developed via the TransCon hGH platform Sandoz Swiss Exchange: SDZ Omnitrope (GH); Sandoz became an independent listed company in 2023 OPKO Health NASDAQ (USA): OPK Co-develops and commercializes NGENLA with Pfizer, and receives related revenues per agreement Merck KGaA (Germany) Frankfurt Stock Exchange (Germany): MRK Saizen (GH); refers to the German Merck Group LG Chem Korea Exchange: 051910 Markets Eutropin-series GH products through its life sciences business Notably, Pfizer and OPKO jointly participate in NGENLA—a case illustrating that, when analyzing listed-company strategies, one must consider not only brand names but also the distinct parties responsible for technology development, manufacturing, and commercialization rights. This enterprise list requires continuous updating.

The global anaerobic culture device market sales revenue is projected to reach approximately RMB 21.8 billion in 2026, with automation and intelligence as core development directions [Chart].

Table of Contents 1 Overview of the Anaerobic Culture Device Market 1.1 Product Definition and Scope of Statistics 1.2 Classification of Anaerobic Culture Devices by Product Type 1.2.1 Global Sales Revenue Growth Trends of Different Anaerobic Culture Device Types: 2021 vs. 2025 vs. 2032 1.2.2 Anaerobic Culture Media 1.2.3 Anaerobic Culture Jars 1.2.4 Anaerobic Culture Chambers 1.2.5 Others 1.3 Applications of Anaerobic Culture Devices 1.3.1 Global Sales Revenue Growth Trends of Anaerobic Culture Devices by Application: 2021 vs. 2025 vs. 2032 1.3.2 Healthcare 1.3.3 Food & Beverage 1.3.4 Chemical Industry 1.3.5 Biotechnology 1.3.6 Agriculture 1.3.7 Others 1.4 Industry Background, Development History, Current Status, and Trends 1.4.1 Current Status Analysis of the Anaerobic Culture Device Industry 1.4.2 Development Trends of the Anaerobic Culture Device Industry 2 Global Overall Market Size Analysis of Anaerobic Culture Devices 2.1 Global Supply-Demand Status and Forecast for Anaerobic Culture Devices (2021–2032) 2.1.1 Global Capacity, Output, Capacity Utilization Rate, and Development Trends of Anaerobic Culture Devices (2021–2032) 2.1.2 Global Output, Demand Volume, and Development Trends of Anaerobic Culture Devices (2021–2032) 2.2 Global Major Regional Output and Development Trends of Anaerobic Culture Devices (2021–2032) 2.2.1 Global Major Regional Output of Anaerobic Culture Devices (2021–2026) 2.2.2 Global Major Regional Output of Anaerobic Culture Devices (2027–2032) 2.2.3 Global Major Regional Output Market Share of Anaerobic Culture Devices (2021–2032) 2.3 China’s Supply-Demand Status and Forecast for Anaerobic Culture Devices (2021–2032) 2.3.1 China’s Capacity, Output, Capacity Utilization Rate, and Development Trends of Anaerobic Culture Devices (2021–2032) 2.3.2 China’s Output, Market Demand Volume, and Development Trends of Anaerobic Culture Devices (2021–2032) 2.4 Global Sales Volume and Revenue of Anaerobic Culture Devices 2.4.1 Global Market Revenue of Anaerobic Culture Devices (2021–2032) 2.4.2 Global Market Sales Volume of Anaerobic Culture Devices (2021–2032) 2.4.3 Global Market Price Trends of Anaerobic Culture Devices (2021–2032) 3 Regional Analysis of Global Anaerobic Culture Devices 3.1 Analysis of Major Regional Market Sizes for Anaerobic Culture Devices: 2021 vs. 2025 vs. 2032 3.1.1 Revenue and Market Share of Anaerobic Culture Devices in Major Global Regions (2021–2026) 3.1.2 Revenue Forecast for Anaerobic Culture Devices in Major Global Regions (2027–2032) 3.2 Analysis of Sales Volume of Anaerobic Culture Devices in Major Global Regions: 2021 vs. 2025 vs. 2032 3.2.1 Sales Volume and Market Share of Anaerobic Culture Devices in Major Global Regions (2021–2026)

Merck KGaA opens bioprocessing production center in South Korea

11 hours ago

Merck KGaA has opened a €300 million bioprocessing production center in Daejeon, South Korea, marking its largest life science investment in APAC. The facility expands capacity for critical materials used in biologic medicine development and manufacturing.

chemweek

2025-11-13

Merck KGaA tightens guidance; Q3 earnings rise, beat estimates

2025-11-20

Merck KGaA launches supercomputer to advance innovation

2026-01-20

Merck KGaA partners with technology firm in Singapore to improve chemical R&D

2026-03-05

Merck KGaA posts decline in earnings on negative currency effects

2026-05-13

Merck Lifts 2026 Profit, Sales Outlook on Life Science, Healthcare Resilience